CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (USD $) In Thousands	6 Months Ended
	Jun. 30, 2011		Jun. 30, 2010
Cash flows from operating activities:
Net loss before non-controlling interest	$ (4,848)		$ (5,805)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss from discontinued operations	0		234
Stock-based compensation expense	191		865
Depreciation	42		74
Accrued interest	0		(3)
Assignment of Medicsight stock to D4D	(4)		0
Gain on sale of loan receivable - related party	(81)		0
Profit on disposal of Medicexchange and other investments	0		(201)
(Increase)/decrease in assets
Accounts receivable	(176)		34
Other receivable - related party	47		(194)
Prepaid expenses and other current assets	(337)		19
Increase/(decrease) in liabilities
Accounts payable	197		(332)
Accrued expenses	(154)		(116)
Other payables	0		5
Net cash used in operating activities	(5,123)		(5,420)
Cash flows from investing activities:
Issuance of Moneygate loans receivable	0		(1,370)
Cash in Medicexchange subsidiaries disposed of	0		(1,101)
Receipt of Dunamis loan repayment	1,100		0
Purchase of property, plant and equipment	0		(40)
Receipts from sale of Moneygate	401		0
Receipts of deferred consideration for sale of assets	370		382
Receipts from sale of Medicsight’s stock	110		0
Net cash used in investing activities	1,981		(2,129)
Cash flows of discontinued operations
Net cash used in Medicexchange operating activities	0		(226)
Net cash used in discontinued operations	0		(226)
Effects of exchange rates on cash and cash equivalents	412		(1,060)
Net change in cash and cash equivalents	(2,730)		(8,835)
Cash and cash equivalents, beginning of period	8,434	[1]	22,165
Cash and cash equivalents, end of period	$ 5,704		$ 13,330

[1] Derived from audited financial information